“…It must be pointed out that FOSB immunoreactivity is not specific for EH. As stated above, PHE is defined by a recurrent Positive for either CAMTA1 27,42 or TFE3 35,42,43 ; negative for FOSB 29 Often positive for D2-40/podoplanin 43 ; MYC-negative; INI1 preserved 43,44 Angiosarcoma (AS) Negative for FOSB 29 , CAMTA1 27,42 Often co-expressing D2-40/podoplanin and c-MYC 38,39 Epithelioid angiosarcoma (EAS) Negative for FOSB, 27,29 CAMTA1 27,42 Often (focal) co-expression of cytokeratin and EMA 45,46 ; ERG-positive 47 Pseudomyogenic/epithelioid sarcoma-like hemangioendothelioma (PHE) 36 Co-expression of FOSB 27,29 and AE1/AE3 27,48 Negative for pan-cytokeratin MNF116 49 ; INI1 preserved 48,49 Epithelioid sarcoma (ES) INI1 (SMARCB3)-negative 44,50 Mostly ERG-negative 47 (ERG-expression extremely rare); negative for CAMTA1 27,42 , FOSB 27,29 Cutaneous epithelioid angiomatous nodule Negative for FOSB 29 This study adds to previous evidence of the oncogenic role of FOSB in the pathogenesis of endothelial neoplasms, such as EH and PHE.…”